By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – One day after Exact Sciences announced its second-quarter earnings and provided details about the clinical trial for its colorectal cancer screening test, Wall Street reacted in mixed fashion, as several analysts increased their loss-per-share estimates for 2011 and 2012, and one downgraded Exact Sciences' stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.